Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States.
$2.71-0.92%
报价 2026-11-06
市值
$4.1M
EV
$21.2M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -93.1%
$1.60$39.00
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
market cap below $300M floor
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| APUSApimeds Pharmaceuticals US, Inc | $4.1M | -0.9% | – | 0% | – | – | – | |
| QTTBQ32 Bio Inc. | $275.4M | +4.5% | 0.0% | 99.8% | 3.1x | 4.5x | – | |
| ANTXAN2 Therapeutics, Inc. | $150.9M | +1.1% | +119.0% | 0% | – | – | – | |
| TLPHTalphera, Inc. | $54.5M | +4.0% | +29430.6% | -4,075% | – | – | – | |
| POCIPrecision Optics Corporation, Inc. | $53.6M | -1.3% | – | 9.7% | – | – | – | |
| MYOMyomo, Inc. | $47.9M | +1.7% | +11.0% | 68.4% | – | – | – | |
| MLSSMilestone Scientific Inc. | $27.4M | +1.0% | +7.6% | 69.6% | – | – | – | |
| NXTCNextCure, Inc. | $24.4M | +4.1% | -85.2% | 0% | – | – | – | |
| MIRAMIRA Pharmaceuticals, Inc. | $24M | +5.6% | – | 0% | – | – | – | |
| 同行中位数 | – | – | +9.3% | 4.9% | 3.1x | 4.5x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。
研究材料
Filing 摘要
电话会纪要摘要
暂无纪要摘要。